Tech Company Financing Transactions
NanoPhoria Bioscience Funding Round
NanoPhoria Bioscience closed a $18 million funding round on 2/26/2025. Investors included European Innovation Council Fund.
Transaction Overview
Company Name
Announced On
2/26/2025
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$18,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to support advancement of its lead product for heart failure through first-in-human studies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Via Visconti di Modrone, 18
Milan, 20122
Italy
Milan, 20122
Italy
Phone
Undisclosed
Website
Email Address
Overview
NanoPhoria is a preclinical stage biotech company pioneering inhalable cardiovascular treatments via non-viral nano-delivery of biologics. The Company is devoted to the clinical development of an innovative proprietary platform for the tissue-directed delivery of therapeutic peptides and RNAs. The core vehicle is an inorganic calcium-phosphate nanoparticle which represents a versatile, biomimetic nano-carrier that can be loaded or surface decorated with biologics and can be formulated for inhalation or for other administration routes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Claudio De Luca
Browse more venture capital transactions:
Prev: 2/26/2025: Aegis venture capital transaction
Next: 2/26/2025: Loyal for Dogs venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs